BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13(39): 5188-5195 [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188]
URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5188.htm
Number Citing Articles
1
Koji Waki, Hiroshi Aikata, Yoshio Katamura, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Shoichi Takahashi, Naoyuki Toyota, Katsuhide Ito, Kazuaki Chayama. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow upJournal of Gastroenterology and Hepatology 2010; 25(3): 597 doi: 10.1111/j.1440-1746.2009.06125.x
2
Mark W. Russo. Erratum to: The Role of Interferon Therapy in Patients With Hepatocellular CarcinomaCurrent Hepatitis Reports 2009; 8(S1): 35 doi: 10.1007/s11901-011-0088-0
3
Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan. Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic ResectionAnnals of Surgical Oncology 2012; 19(2): 418 doi: 10.1245/s10434-011-1866-1
4
Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinomaJournal of Viral Hepatitis 2010; 17(4): 287 doi: 10.1111/j.1365-2893.2009.01181.x
5
T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan, K. Chayama. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinomaJournal of Viral Hepatitis 2011; 18(10): e550 doi: 10.1111/j.1365-2893.2011.01468.x
6
Wei Teng, Wen-Juei Jeng, Hwai-I Yang, Wei-Ting Chen, Yi-Chung Hsieh, Chien-Hao Huang, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular CarcinomaCancers 2019; 12(1): 23 doi: 10.3390/cancers12010023
7
Shoji Kubo. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapyClinical Journal of Gastroenterology 2009; 2(2): 65 doi: 10.1007/s12328-009-0072-1
8
Soji Shimomura, Shuhei Nishiguchi. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infectionHepatology Research 2012; 42(1): 22 doi: 10.1111/j.1872-034X.2011.00889.x
9
Hong-Bo Huan, Li-Li Wu, Wan-Yee Lau, Xu-Dong Wen, Liang Zhang, Da-Peng Yang, Xi-Shu Wang, Ping Bie, Feng Xia. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ dataOncotarget 2017; 8(52): 90291 doi: 10.18632/oncotarget.18853
10
T.-S. Huang, Y.-C. Shyu, H.-Y. Chen, S.-S. Yuan, J.-N. Shih, P.-J. Chen. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinomaJournal of Viral Hepatitis 2013; 20(10): 729 doi: 10.1111/jvh.12096
11
Chia-Chi Wang, Jia-Horng Kao. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?Expert Opinion on Pharmacotherapy 2016; 17(7): 911 doi: 10.1517/14656566.2016.1149165
12
A. V. Borsukov, O. A. Gorbatenko, D. Yu. Venidiktova, A. O. Tagil, A. A. Kovalev. Multiparametric Ultrasound in the Diagnosis of Hepatocellular Carcinoma in Patients without Cirrhosis (Clinical Case)Journal of oncology: diagnostic radiology and radiotherapy 2020; 3(1): 86 doi: 10.37174/2587-7593-2020-3-1-86-93
13
Yuko Nagaoki, Hiroshi Aikata, Tomoki Kobayashi, Takayuki Fukuhara, Keiichi Masaki, Mio Tanaka, Noriaki Naeshiro, Takashi Nakahara, Yohji Honda, Daisuke Miyaki, Tomokazu Kawaoka, Shintaro Takaki, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Yoshiiku Kawakami, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosisJournal of Gastroenterology 2013; 48(7): 847 doi: 10.1007/s00535-012-0679-8
14
Hiroaki Hagihara, Kazuhiro Nouso, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shinichiro Nakamura, Kenji Kuwaki, Junichi Toshimori, Hirokazu Miyatake, Hideki Ohnishi, Hidenori Shiraha, Kazuhide Yamamoto. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinomaInternational Journal of Clinical Oncology 2011; 16(3): 210 doi: 10.1007/s10147-010-0150-x
15
Masatoshi Kudo. Prevention of Recurrence of Liver CancerNihon Naika Gakkai Zasshi 2008; 97(7): 1681 doi: 10.2169/naika.97.1681
16
Hengjun Gao, Minshan Chen. Radiofrequency Ablation for Small Hepatocellular Carcinoma2016; : 85 doi: 10.1007/978-94-017-7258-7_10
17
WEI ZHANG, TIAN-QIANG SONG, TI ZHANG, QIANG WU, DA-LU KONG, QIANG LI, HUI-CHUAN SUN. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitisMolecular and Clinical Oncology 2014; 2(6): 1125 doi: 10.3892/mco.2014.386
18
Ying-Chun Shen, Chiun Hsu, Li-Tzong Chen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approachJournal of Hepatology 2010; 52(6): 889 doi: 10.1016/j.jhep.2009.12.041
19
Yan Du, Tong Su, Yibo Ding, Guangwen Cao. Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver TransplantationHepatitis Monthly 2012; 12(10) doi: 10.5812/hepatmon.6031
20
Gabriella Lengyel, János Fehér†. Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinomaOrvosi Hetilap 2010; 151(29): 1177 doi: 10.1556/oh.2010.28925
21
Masatoshi Kudo. Adjuvant Therapy after Curative Treatment for Hepatocellular CarcinomaOncology 2011; 81(s1): 50 doi: 10.1159/000333259
22
Mark W. Russo. The Role of Interferon Therapy in Patients with Hepatocellular CarcinomaCurrent Hepatitis Reports 2012; 11(4): 279 doi: 10.1007/s11901-010-0075-x